HVTN 302: A phase 1, randomized, open-label clinical trial to evaluate the safety and immunogenicity of HIV trimer mRNA vaccines in healthy, HIV-uninfected adult participants.

RELEVANCE: Development of effective vaccines to protect individuals against HIV is a challenging and growing public health priority. The HVTN’s mission is to fully characterize the safety, immunogenicity, and efficacy of HIV vaccine candidates with the goal of developing a safe, effective vaccine as rapidly as possible for prevention of HIV globally.

DESCRIPTION: The HVTN 302 study is a phase 1 clinical trial looking to evaluate the safety and immunogenicity (how the immune system responds) to three different HIV trimer mRNA vaccines in healthy, HIV uninfected adults.

STATUS: This study is currently active. We have reached full enrollment and are not recruiting additional participants.